Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus

Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after init...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Alyson, DeHaan, Elliott, Maltz, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443835/
https://www.ncbi.nlm.nih.gov/pubmed/34549064
http://dx.doi.org/10.14309/crj.0000000000000594
_version_ 1784568374407200768
author Kaplan, Alyson
DeHaan, Elliott
Maltz, Charles
author_facet Kaplan, Alyson
DeHaan, Elliott
Maltz, Charles
author_sort Kaplan, Alyson
collection PubMed
description Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.
format Online
Article
Text
id pubmed-8443835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-84438352021-09-20 Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus Kaplan, Alyson DeHaan, Elliott Maltz, Charles ACG Case Rep J Case Report Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy. Wolters Kluwer 2021-05-19 /pmc/articles/PMC8443835/ /pubmed/34549064 http://dx.doi.org/10.14309/crj.0000000000000594 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kaplan, Alyson
DeHaan, Elliott
Maltz, Charles
Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title_full Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title_fullStr Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title_full_unstemmed Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title_short Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
title_sort reactivation of hepatitis b after ibalizumab therapy for multidrug-resistant human immunodeficiency virus
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443835/
https://www.ncbi.nlm.nih.gov/pubmed/34549064
http://dx.doi.org/10.14309/crj.0000000000000594
work_keys_str_mv AT kaplanalyson reactivationofhepatitisbafteribalizumabtherapyformultidrugresistanthumanimmunodeficiencyvirus
AT dehaanelliott reactivationofhepatitisbafteribalizumabtherapyformultidrugresistanthumanimmunodeficiencyvirus
AT maltzcharles reactivationofhepatitisbafteribalizumabtherapyformultidrugresistanthumanimmunodeficiencyvirus

Ejemplares similares